

# Hermann L MÃ¼ller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9541205/publications.pdf>

Version: 2024-02-01

146  
papers

7,535  
citations

47006

47  
h-index

60623

81  
g-index

154  
all docs

154  
docs citations

154  
times ranked

3464  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. <i>Journal of Biological Chemistry</i> , 1993, 268, 14964-71.	3.4	314
2	Craniopharyngioma. <i>Endocrine Reviews</i> , 2014, 35, 513-543.	20.1	295
3	Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells.. <i>Journal of Biological Chemistry</i> , 1993, 268, 26045-26048.	3.4	277
4	Craniopharyngioma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 75.	30.5	255
5	Longitudinal Study on Growth and Body Mass Index before and after Diagnosis of Childhood Craniopharyngioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3298-3305.	3.6	247
6	Obesity after childhood craniopharyngioma - German multicenter study on pre-operative risk factors and quality of life. <i>Klinische Padiatrie</i> , 2001, 213, 244-249.	0.6	242
7	Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. <i>European Journal of Endocrinology</i> , 2011, 165, 17-24.	3.7	234
8	Transforming Growth Factor- $\beta$ 2-induced Cell Growth Inhibition in Human Breast Cancer Cells Is Mediated through Insulin-like Growth Factor-binding Protein-3 Action. <i>Journal of Biological Chemistry</i> , 1995, 270, 13589-13592.	3.4	215
9	Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. <i>Journal of Biological Chemistry</i> , 1993, 268, 26045-8.	3.4	213
10	Obesity in Patients with Craniopharyngioma: Assessment of Food Intake and Movement Counts Indicating Physical Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5227-5231.	3.6	195
11	Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. <i>Neuro-Oncology</i> , 2015, 17, 1029-1038.	1.2	167
12	Melatonin Secretion and Increased Daytime Sleepiness in Childhood Craniopharyngioma Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3993-3996.	3.6	155
13	Childhood craniopharyngioma—current concepts in diagnosis, therapy and follow-up. <i>Nature Reviews Endocrinology</i> , 2010, 6, 609-618.	9.6	155
14	Consequences of Craniopharyngioma Surgery in Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1981-1991.	3.6	153
15	Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. <i>Child's Nervous System</i> , 2005, 21, 975-980.	1.1	116
16	Melatonin Treatment in Obese Patients with Childhood Craniopharyngioma and Increased Daytime Sleepiness. <i>Cancer Causes and Control</i> , 2006, 17, 583-589.	1.8	111
17	Childhood Craniopharyngioma. <i>Hormone Research in Paediatrics</i> , 2008, 69, 193-202.	1.8	110
18	Hypothalamic obesity in children. <i>Obesity Reviews</i> , 2012, 13, 780-798.	6.5	106

#	ARTICLE	IF	CITATIONS
19	New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. <i>Nature Reviews Endocrinology</i> , 2017, 13, 299-312.	9.6	105
20	Xanthogranuloma, Rathke's Cyst, and Childhood Craniopharyngioma: Results of Prospective Multinational Studies of Children and Adolescents with Rare Sellar Malformations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3935-3943.	3.6	102
21	Reduced Sympathetic Metabolites in Urine of Obese Patients With Craniopharyngioma. <i>Pediatric Research</i> , 2007, 61, 496-501.	2.3	96
22	Functional Capacity, Obesity and Hypothalamic Involvement: Cross-Sectional Study on 212 Patients with Childhood Craniopharyngioma. <i>Klinische Padiatrie</i> , 2003, 215, 310-314.	0.6	90
23	Childhood craniopharyngioma. <i>Pituitary</i> , 2013, 16, 56-67.	2.9	86
24	Analyses of Treatment Variables for Patients with Childhood Craniopharyngioma – Results of the Multicenter Prospective Trial KRANIOPHARYNGEOM 2000 after Three Years of Follow-Up. <i>Hormone Research in Paediatrics</i> , 2010, 73, 175-180.	1.8	83
25	Craniopharyngioma and hypothalamic injury. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 81-89.	2.3	82
26	The Diagnosis and Treatment of Craniopharyngioma. <i>Neuroendocrinology</i> , 2020, 110, 753-766.	2.5	74
27	Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 428-434.	3.6	72
28	Radical Surgery in a Neonate with Craniopharyngioma. <i>Pediatric Neurosurgery</i> , 2000, 33, 265-269.	0.7	71
29	Appetite-Regulating Hormone Changes in Patients With Craniopharyngioma. <i>Obesity</i> , 2011, 19, 36-42.	3.0	71
30	Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. <i>Neuro-Oncology</i> , 2017, 19, 1398-1407.	1.2	68
31	Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. <i>Progress in Growth Factor Research</i> , 1995, 6, 503-512.	1.6	67
32	Prognosis and Sequela in Patients with Childhood Craniopharyngioma - Results of HIT-ENDO and Update on KRANIOPHARYNGEOM 2000. <i>Klinische Padiatrie</i> , 2004, 216, 343-348.	0.6	67
33	A systematic review of cognitive performance in patients with childhood craniopharyngioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 9-21.	2.9	65
34	First Experiences with Laparoscopic Adjustable Gastric Banding (LAGB) in the Treatment of Patients with Childhood Craniopharyngioma and Morbid Obesity. <i>Klinische Padiatrie</i> , 2007, 219, 323-325.	0.6	63
35	History before diagnosis in childhood craniopharyngioma: associations with initial presentation and long-term prognosis. <i>European Journal of Endocrinology</i> , 2015, 173, 853-862.	3.7	62
36	Neuropsychological Outcome in Patients with Childhood Craniopharyngioma and Hypothalamic Involvement. <i>Journal of Pediatrics</i> , 2014, 164, 876-881.e4.	1.8	60

#	ARTICLE	IF	CITATIONS
37	Perioperative Dexamethasone Treatment in Childhood Craniopharyngioma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 330-334.	1.2	59
38	Melatonin Secretion and Increased Daytime Sleepiness in Childhood Craniopharyngioma Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3993-3996.	3.6	56
39	Childhood Craniopharyngioma – Changes of Treatment Strategies in the Trials KRANIOPHARYNGEOM 2000/2007. <i>Klinische Padiatrie</i> , 2014, 226, 161-168.	0.6	56
40	Increased Daytime Sleepiness in Patients with Childhood Craniopharyngioma and Hypothalamic Tumor Involvement: Review of the Literature and Perspectives. <i>International Journal of Endocrinology</i> , 2010, 2010, 1-7.	1.5	55
41	Brain-derived neurotrophic factor and its relation to leptin in obese children before and after weight loss. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 226-234.	3.4	54
42	Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, nlw116.	1.7	54
43	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 151-166.	7.2	53
44	Oxytocin in survivors of childhood-onset craniopharyngioma. <i>Endocrine</i> , 2016, 54, 524-531.	2.3	51
45	Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. <i>Endocrine</i> , 2018, 59, 364-372.	2.3	51
46	Relapse Pattern After Complete Resection and Early Progression After Incomplete Resection of Childhood Craniopharyngioma. <i>Klinische Padiatrie</i> , 2006, 218, 315-320.	0.6	50
47	Surgical strategy and quality of life in craniopharyngioma. <i>Nature Reviews Endocrinology</i> , 2013, 9, 447-449.	9.6	50
48	Neuroendocrine Disorders in Pediatric Craniopharyngioma Patients. <i>Journal of Clinical Medicine</i> , 2015, 4, 389-413.	2.4	50
49	Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. <i>European Journal of Endocrinology</i> , 2015, 173, 389-397.	3.7	50
50	Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 428-434.	3.6	50
51	Functional capacity and body mass index in patients with sellar masses – cross-sectional study on 403 patients diagnosed during childhood and adolescence. <i>Child's Nervous System</i> , 2005, 21, 539-545.	1.1	48
52	Diencephalic Syndrome in Childhood Craniopharyngioma – Results of German Multicenter Studies on 485 Long-term Survivors of Childhood Craniopharyngioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3972-3977.	3.6	46
53	Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. <i>Endocrine Connections</i> , 2019, 8, 481-492.	1.9	46
54	A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. <i>Journal of Neuro-Oncology</i> , 1998, 38, 19-26.	2.9	44

#	ARTICLE	IF	CITATIONS
55	Volumetric Bone Mineral Density in Patients with Childhood Craniopharyngioma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 168-173.	1.2	44
56	Changes of peripheral $\alpha$ -melanocyte-stimulating hormone in childhood obesity. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 186-194.	3.4	44
57	Craniopharyngioma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 124, 235-253.	1.8	44
58	Hydrocephalus and hypothalamic involvement in pediatric patients with craniopharyngioma or cysts of Rathke's pouch: impact on long-term prognosis. <i>European Journal of Endocrinology</i> , 2015, 172, 561-569.	3.7	44
59	Long-Term Follow-Up of Morbidly Obese Patients with Childhood Craniopharyngioma after Laparoscopic Adjustable Gastric Banding (LAGB). <i>Klinische Padiatrie</i> , 2011, 223, 372-373.	0.6	43
60	Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2015, 28, 35-43.	0.9	42
61	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. <i>European Journal of Endocrinology</i> , 2022, 186, P35-P52.	3.7	42
62	Hypothalamic syndrome. <i>Nature Reviews Disease Primers</i> , 2022, 8, 24.	30.5	42
63	Childhood craniopharyngioma: current controversies on management in diagnostics, treatment and follow-up. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 515-524.	2.8	41
64	First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. <i>Endocrine</i> , 2017, 56, 175-185.	2.3	41
65	Acute Lymphoblastic Leukemia with Severe Skeletal Involvement: A Subset of Childhood Leukemia with a Good Prognosis. <i>Pediatric Hematology and Oncology</i> , 1998, 15, 121-133.	0.8	40
66	Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. <i>European Journal of Pediatrics</i> , 2018, 177, 125-132.	2.7	40
67	Non-receptor mediated, post-transcriptional regulation of insulin-like growth factor binding protein (IGFBP)-3 in Hs578T human breast cancer cells. <i>Endocrinology</i> , 1992, 131, 3123-3125.	2.8	39
68	$\alpha$ -Melanocyte stimulating hormone promotes muscle glucose uptake via melanocortin 5 receptors. <i>Molecular Metabolism</i> , 2016, 5, 807-822.	6.5	39
69	Bridging the gap: metabolic and endocrine care of patients during transition. <i>Endocrine Connections</i> , 2016, 5, R44-R54.	1.9	38
70	Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo). <i>European Journal of Endocrinology</i> , 2018, 179, 331-341.	3.7	38
71	Strategies to improve the quality of survival for childhood brain tumour survivors. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 619-639.	1.6	36
72	Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment, and follow-up. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 793-806.	2.8	36

#	ARTICLE	IF	CITATIONS
73	Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 1113-1119.	3.6	33
74	Risk-adapted, long-term management in childhood-onset craniopharyngioma. <i>Pituitary</i> , 2017, 20, 267-281.	2.9	33
75	Remote effects of hypothalamic lesions in the prefrontal cortex of craniopharyngioma patients. <i>Neurobiology of Learning and Memory</i> , 2014, 111, 71-80.	1.9	32
76	Fusiform dilatation of the internal carotid artery in childhood-onset craniopharyngioma: multicenter study on incidence and long-term outcome. <i>Pituitary</i> , 2016, 19, 422-428.	2.9	32
77	Diagnostics, treatment, and follow-up in craniopharyngioma. <i>Frontiers in Endocrinology</i> , 2011, 2, 70.	3.5	31
78	Childhood craniopharyngioma: treatment strategies and outcomes. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 187-197.	2.8	31
79	Preoperative staging in childhood craniopharyngioma: standardization as a first step towards improved outcome. <i>Endocrine</i> , 2016, 51, 1-3.	2.3	30
80	Characterization of the affinities of insulin-like growth factor (IGF)- binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. <i>Endocrinology</i> , 1993, 132, 1337-1344.	2.8	30
81	MANAGEMENT OF ENDOCRINE DISEASE: Childhood-onset craniopharyngioma: state of the art of care in 2018. <i>European Journal of Endocrinology</i> , 2019, 180, R159-R174.	3.7	30
82	Neonatal Screening: Identification of Children with 11 <sup>β</sup> -Hydroxylase Deficiency by Second-Tier Testing. <i>Hormone Research in Paediatrics</i> , 2012, 77, 195-199.	1.8	29
83	Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese patients with childhood craniopharyngioma. <i>Neuropediatrics</i> , 2006, 37, 423-9.	0.6	29
84	Craniopharyngioma: long-term consequences of a chronic disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1241-1244.	2.8	28
85	Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging. <i>Clinical Cancer Research</i> , 2004, 10, 2997-3006.	7.0	27
86	More or less? Treatment strategies in childhood craniopharyngioma. <i>Child's Nervous System</i> , 2006, 22, 156-157.	1.1	25
87	Ectopic Craniopharyngioma. <i>Klinische Padiatrie</i> , 2011, 223, 176-177.	0.6	25
88	Childhood-onset Craniopharyngioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3820-e3836.	3.6	24
89	Final height and weight of long-term survivors of childhood malignancies. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 135-139.	1.2	20
90	Eating behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of hypothalamic involvement. <i>Pediatric Obesity</i> , 2019, 14, e12527.	2.8	20

#	ARTICLE	IF	CITATIONS
91	Management of Hypothalamic Obesity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 533-552.	3.2	19
92	Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 27-35.	2.9	18
93	Kraniopharyngeom im Kindes- und Jugendalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2003, 151, 1056-1063.	0.1	17
94	Craniopharyngioma " A Childhood and Adult Disease with Challenging Characteristics. <i>Frontiers in Endocrinology</i> , 2012, 3, 80.	3.5	17
95	Meningioma as second malignant neoplasm after oncological treatment during childhood. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 438-441.	2.0	16
96	Hypothalamic tumors impact gray and white matter volumes in fronto-limbic brain areas. <i>Cortex</i> , 2017, 89, 98-110.	2.4	16
97	Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007. <i>Pituitary</i> , 2019, 22, 532-541.	2.9	15
98	Synthesis and Characterization of IGF-II Analogs: Applications in the Evaluation of IGF Receptor Function and IGF-Independent Actions of IGFBPS. <i>Advances in Experimental Medicine and Biology</i> , 1994, 343, 41-54.	1.6	15
99	Asp361Val Mutant of Alkaline Phosphatase Found in Patients with Dominantly Inherited Hypophosphatasia Inhibits the Activity of the Wild-Type Enzyme. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 743-747.	3.6	15
100	Current Strategies in Diagnostics and Endocrine Treatment of Patients with Childhood Craniopharyngioma During Follow-Up " Recommendations in KRANIOPHARYNGEOM 2000. <i>Oncology Research and Treatment</i> , 2005, 28, 150-156.	1.2	14
101	Hypothalamic involvement in craniopharyngioma" Implications for surgical, radiooncological, and molecularly targeted treatment strategies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26936.	1.5	14
102	Risk-adapted treatment and follow-up management in childhood-onset craniopharyngioma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 535-548.	2.8	13
103	DISSEMINATED MALIGNANT ECTOMESENCHYMOMA (MEM): Case Report and Review of the Literature. <i>Pediatric Hematology and Oncology</i> , 2002, 19, 9-17.	0.8	12
104	First report on spinal metastasis in childhood-onset craniopharyngioma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 193-194.	2.9	12
105	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , 2021, 142, 873-886.	7.7	12
106	Non-receptor mediated, post-transcriptional regulation of insulin-like growth factor binding protein (IGFBP)-3 in Hs578T human breast cancer cells. <i>Endocrinology</i> , 1992, 131, 3123-3125.	2.8	11
107	Childhood craniopharyngioma " current status and recent perspectives in diagnostics and treatment. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2015, 28, 1-2.	0.9	10
108	Low concordance between surgical and radiological assessment of degree of resection and treatment-related hypothalamic damage: results of KRANIOPHARYNGEOM 2007. <i>Pituitary</i> , 2018, 21, 371-378.	2.9	9

#	ARTICLE	IF	CITATIONS
109	Pregnancies after Childhood Craniopharyngioma: Results of KRANIOPHARYNGEOM 2000/2007 and Review of the Literature. <i>Neuroendocrinology</i> , 2021, 111, 16-26.	2.5	9
110	Cerebral Infarction in Childhood-Onset Craniopharyngioma Patients: Results of KRANIOPHARYNGEOM 2007. <i>Frontiers in Oncology</i> , 2021, 11, 698150.	2.8	9
111	SIOPODCA“adapted treatment guidelines for craniopharyngioma in low- and middle-income settings. <i>Pediatric Blood and Cancer</i> , 2023, 70, e28493.	1.5	8
112	Social Cognition in Patients With Hypothalamic-Pituitary Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 1014.	2.8	8
113	Hypothalamic-Pituitary Outcome after Treatment for Childhood Craniopharyngioma. <i>Frontiers of Hormone Research</i> , 2021, 54, 47-57.	1.0	8
114	Primary haemophagocytic lymphohistiocytosis (ChÅ©diak-Higashi Syndrome) triggered by acute SARS-CoV-2 infection in a six-week-old infant. <i>British Journal of Haematology</i> , 2021, 195, 198-200.	2.5	8
115	Diagnosis, treatment, clinical course, and prognosis of childhood-onset craniopharyngioma patients. <i>Minerva Endocrinology</i> , 2017, 42, 356-375.	1.1	8
116	Dilatative Uropathy as a Manifestation of Neurohypophyseal Diabetes Insipidus due to a Novel Mutation in the Arginine Vasopressin-Neurophysin-II Gene. <i>Klinische Padiatrie</i> , 2014, 225, 407-412.	0.6	7
117	Nuchal Skinfold Thickness: A Novel Parameter for Assessment of Body Composition in Childhood Craniopharyngioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4922-4930.	3.6	7
118	Needle-Free and Needle-Based Growth Hormone Therapy in Children: A Pooled Analysis of Three Long-Term Observational Studies. <i>Hormone Research in Paediatrics</i> , 2018, 90, 393-406.	1.8	7
119	Cardiac remodeling in patients with childhood-onset craniopharyngioma“results of HIT-Endo and KRANIOPHARYNGEOM 2000/2007. <i>European Journal of Pediatrics</i> , 2021, 180, 1593-1602.	2.7	6
120	Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27487.	1.5	5
121	Craniopharyngioma “ Pediatric Management. , 2015, , 429-458.		4
122	Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 1308-1314.	1.3	4
123	Periostin concentrations in childhood-onset craniopharyngioma patients. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 815-824.	3.3	4
124	Reply to: Understanding treatment options in craniopharyngioma better. <i>Nature Reviews Disease Primers</i> , 2020, 6, 27.	30.5	4
125	Long-Term Management and Clinical Trials in Adamantinomatous Craniopharyngioma. , 2017, , 179-214.		3
126	Disease and Treatment-Related Hypothalamic Alterations in Craniopharyngioma: Clinical Presentation, Prognostic Impact, and Implications for Treatment Strategies. , 2020, , 157-186.		3



#	ARTICLE	IF	CITATIONS
127	Skelettbeschwerden als Leitsymptom der akuten lymphoblastischen Leukämie im Kindesalter. Monatsschrift Fur Kinderheilkunde, 1999, 147, 116-121.	0.1	2
128	Hypothalamic Obesity in Children. Pediatric and Adolescent Medicine, 2015, , 13-30.	0.4	2
129	Bariatric Interventions in Craniopharyngioma Patientsâ€”Best Choice or Last Option for Treatment of Hypothalamic Obesity?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e426-e428.	3.6	2
130	Personalized therapy in craniopharyngiomaâ€”novel perspectives and limitations. Journal of Xiangya Medicine, 0, 2, 71-71.	0.2	2
131	ZNS-Tumoren. , 2018, , 359-418.		2
132	Childhood Craniopharyngioma â€” Current Strategies in Laboratory Diagnostics and Endocrine Treatment/Kraniopharyngeon im Kindes- und Jugendalter â€” Laboratoriumsdiagnostik und hormonelle Therapie. Laboratoriums Medizin, 2003, 27, 377-385.	0.6	1
133	Reactive Pituitary Enlargement Mimicking a Sellar Mass. Klinische Padiatrie, 2014, 226, 377-378.	0.6	1
134	Diagnosis and treatment of craniopharyngioma. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 29-35.	1.4	1
135	Adamantinomatous Craniopharyngioma: Genomics, Radiologic Findings, Clinical, and Prognosis. Contemporary Endocrinology, 2019, , 41-70.	0.1	1
136	RARE-05. Legal degree of disability in childhood-craniopharyngioma survivors during long-term follow-up â€” results of the HIT-ENDO study. Neuro-Oncology, 2022, 24, i10-i10.	1.2	1
137	Childhood-onset craniopharyngiomas. , 2021, , 521-540.		0
138	Gonadal function of young adults after therapy of malignancies during childhood or adolescence. European Journal of Pediatrics, 1996, 155, 763-769.	2.7	0
139	Kraniopharyngeome bei Kindern. , 2018, , 457-470.		0
140	RARE-59. CARDIAC REMODELING IN PATIENTS WITH CHILDHOOD-ONSET CRANIOPHARYNGIOMA â€” RESULTS OF HIT-ENDO AND KRANIOPHARYNGEOM 2000/2007. Neuro-Oncology, 2020, 22, iii455-iii455.	1.2	0
141	Nuchal Skinfold Thickness in Pediatric Brain Tumor Patients. Frontiers in Endocrinology, 2021, 12, 772856.	3.5	0
142	RARE-04. Hypothalamic syndrome â€” severe sequelae due to different sellar and parasellar masses. Neuro-Oncology, 2022, 24, i9-i10.	1.2	0
143	RARE-02. Craniopharyngiomas diagnosed as incidentalomas - results of KRANIOPHARYNGEOM 2007. Neuro-Oncology, 2022, 24, i9-i9.	1.2	0
144	RARE-03. Vision-related quality of life in patients with childhood-onset craniopharyngioma â€” results of KRANIOPHARYNGEOM 2000 / 2007. Neuro-Oncology, 2022, 24, i9-i9.	1.2	0

#	ARTICLE	IF	CITATIONS
145	RARE-09. Treatment of childhood-onset craniopharyngioma patients using proton beam therapy versus photon-based radiation therapy in the prospective KRANIOPHARYNGEOM 2007 trial. Neuro-Oncology, 2022, 24, i11-i11.	1.2	0
146	RARE-14. Newborn with hypothalamic hamartoma and Pallister-Hall syndrome. Neuro-Oncology, 2022, 24, i12-i12.	1.2	0